Skip to main content
SpringerLink
Log in

Impact of Cytogenetics on Clinical Outcome in AML

  • Chapter
Acute Myelogenous Leukemia

Part of the book series: Contemporary Hematology ((CH))

Abstract

Over the last three decades it has become clear that a significant proportion of cases of acute myeloid leukemia (AML) are characterized by at least one of a variety of recurrent chromosomal abnormalities. While there has been uncertainty as to which represent primary events in the pathogenesis of AML, those that provide oritical second hits that are required for progression to full-blown leukemia or those that are merely markers of the leukemic process, it is nevertheless clear that diagnostic karyotype is a key determinant of outcome in this disease. Moreover, there is mounting evidence to support the notion that cytogenetic analysis can serve to identify biologically distinct subsets of AML that demand tailored therapeutic approaches. This underpins the trend toward more widespread adoption of routine cytogenetic and molecular analysis in the characterization of patients with a diagnosis of acute leukemia. A key challenge for the future is to use information gained from cytogenetic analyses in conjunction with molecular diagnostics and gene expression profiling to achieve greater consensus in risk group assignment of AML, which will provide a more reliable framework for determining the most appropriate treatment approach for individual patients with this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004;18:115–136.

    Article  PubMed  Google Scholar 

  2. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21:2123–2137.

    Article  CAS  PubMed  Google Scholar 

  3. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529–1538.

    Article  CAS  PubMed  Google Scholar 

  4. Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 2002;16:2366–2378.

    Article  CAS  PubMed  Google Scholar 

  5. Schoch C, Haferlach T, Haase D, et al. German AML Cooperative Group. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001;112:118–126.

    Article  CAS  PubMed  Google Scholar 

  6. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 1996;10:1288–1295.

    CAS  PubMed  Google Scholar 

  7. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with AML: analysis of 1,065 patients entered into the MRC AML11 trial. Blood 2001;98:1312–1320.

    Article  CAS  PubMed  Google Scholar 

  8. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075–4083.

    CAS  PubMed  Google Scholar 

  9. Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia—analysis of 848 patients. Leukemia 2001;15:903–909.

    Article  CAS  PubMed  Google Scholar 

  10. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study. Blood 1997;90:2931–2938.

    CAS  PubMed  Google Scholar 

  11. Grimwade D, Walker H, Oliver F, et al. on behalf of the Medical Research Council Adult and Children’s Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML10 trial. Blood 1998;92:2322–2333.

    CAS  PubMed  Google Scholar 

  12. Huntly BJP, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors Cancer Cell 2004;6:587–596.

    Article  CAS  PubMed  Google Scholar 

  13. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 1997;3:730–737.

    Article  CAS  PubMed  Google Scholar 

  14. Caligiuri M, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996;56:1418–1425.

    CAS  PubMed  Google Scholar 

  15. Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in M0 acute myeloid leukemia and in myeloid malignancies with acquired trsomy 21. Blood 2000;96:2862–2869.

    CAS  PubMed  Google Scholar 

  16. Fröhling S, Schlenk RF, Krauter J, et al. Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes and Cancer 2005; 42:427–432.

    Article  PubMed  Google Scholar 

  17. Grimwade D, Biondi A, Mozziconacci M-J, et al. Characterization of acute promyelocytic leukemia cases lacking the classical t(15;17): results of the European working party. Blood 2000;96:1297–1308.

    CAS  PubMed  Google Scholar 

  18. Öhler L, Berer A, Aletaha D, et al. Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth. Br J Haematol 2001;113:120–125.

    Article  PubMed  Google Scholar 

  19. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999;94:1761–1772.

    CAS  PubMed  Google Scholar 

  20. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173–4179.

    CAS  PubMed  Google Scholar 

  21. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998;351:700–708.

    Article  CAS  PubMed  Google Scholar 

  22. Burnett AK, Wheatley K, Goldstone AH, et al. Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML10 trial. Br J Haematol 2002;118:385–400.

    Article  PubMed  Google Scholar 

  23. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999;93:4131–4143.

    CAS  PubMed  Google Scholar 

  24. Haferlach T, Kohlmann A, Schnittger S, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005;106:1189–1198.

    Article  CAS  PubMed  Google Scholar 

  25. Valk PJM, Verhaak RGW, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617–1628.

    Article  CAS  PubMed  Google Scholar 

  26. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics—interaction with other gene mutations. Blood 2005;106:3740–3746.

    Article  PubMed  Google Scholar 

  27. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266.

    Article  CAS  PubMed  Google Scholar 

  28. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733–3739.

    Article  CAS  PubMed  Google Scholar 

  29. Kottaridis PD, Gale RE, Linch DC. FLT3 mutations and leukaemia. Br J Haematol 2003;122:523–538.

    Article  CAS  PubMed  Google Scholar 

  30. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients >60 years. Blood 2005;106:2113–2119.

    Article  CAS  PubMed  Google Scholar 

  31. Reilly JT. Pathogenesis of acute myeloid leukaemia and inv(16)(p13q22): a paradigm for understanding leukaemogenesis? Br J Haematol 2005;128:18–34.

    Article  CAS  PubMed  Google Scholar 

  32. Sith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. New Engl J Med 2004;351:2403–2407.

    Article  Google Scholar 

  33. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002;20:3254–3261.

    Article  PubMed  Google Scholar 

  34. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000;14:796–804.

    Article  CAS  PubMed  Google Scholar 

  35. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemia. Cancer Res 2005;65:375–378.

    CAS  PubMed  Google Scholar 

  36. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 2005;352:1779–1790.

    Article  CAS  PubMed  Google Scholar 

  37. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624–633.

    Article  PubMed  Google Scholar 

  38. Preudhomme C, Sagot C, Boissel N, et al. ALFA Group. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717–2723.

    Article  CAS  PubMed  Google Scholar 

  39. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients excluding acute promyelocytic leukemia from the UK MRC AML10 and 12 trials. Blood, 2005;106:3658–3665.

    Article  CAS  PubMed  Google Scholar 

  40. Marcucci G, Mrózek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461. J Clin Oncol 2004;22:2410–2418.

    Article  PubMed  Google Scholar 

  41. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102: 2395–2402.

    Article  CAS  PubMed  Google Scholar 

  42. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 2002;100:4325–4336.

    Article  CAS  PubMed  Google Scholar 

  43. Suciu S, Mandelli F, de Witte T, et al. EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003;102:1232–1240.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Molecular Genetics, King’s College London, London, UK

    David Grimwade

  2. Department of Haematology, University College London Hospitals, London, UK

    David Grimwade

Authors
  1. David Grimwade
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

    Judith E. Karp MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Grimwade, D. (2007). Impact of Cytogenetics on Clinical Outcome in AML. In: Karp, J.E. (eds) Acute Myelogenous Leukemia. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-322-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-322-6_8

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-621-4

  • Online ISBN: 978-1-59745-322-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation